Ascendis Pharma A/S - ADR (ASND)

Historical Holders from Q1 2015 to Q4 2025

Type / Class
Equity / ADR
Symbol
ASND on Nasdaq
Shares outstanding
55,574,229
Price per share
$213.24
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
63,798,122
Total reported value
$12,683,766,165
% of total 13F portfolios
0.02%
Share change
+1,080,402
Value change
+$232,138,542
Avg buy value change
+0%
Avg sell value change
-0.01%
Number of holders
276
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Ascendis Pharma A/S - ADR (ASND) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WESTFIELD CAPITAL MANAGEMENT CO LP 9.2% $788,713,858 5,528,239 Westfield Capital Management Company, L.P. 31 Dec 2024
FMR LLC 8% $662,979,358 4,646,943 FMR LLC 31 Mar 2025
JANUS HENDERSON GROUP PLC 7.8% -2.5% $859,467,360 -$20,821,968 4,323,059 -2.4% JANUS HENDERSON GROUP PLC 30 Sep 2025
Capital International Investors 5.6% $611,460,188 3,109,225 Capital International Investors 30 Jun 2025
T. Rowe Price Investment Management, Inc. 4.8% -27% $530,338,200 -$182,106,580 2,667,563 -26% T. Rowe Price Investment Management, Inc. 30 Sep 2025
As of 30 Sep 2025, Ascendis Pharma A/S - ADR (ASND) has 276 institutional shareholders filing 13F forms. They hold 63,798,122 shares. .

Top 25 institutional shareholders own 97% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 19% 10,281,496 0% 25% $2,044,064,220
WESTFIELD CAPITAL MANAGEMENT CO LP 9.5% 5,259,909 -3.5% 4.4% $1,045,722,561
Avoro Capital Advisors LLC 9.2% 5,110,000 +2.6% 13% $1,015,919,100
FMR LLC 8% 4,471,733 -1.3% 0.05% $889,025,151
JANUS HENDERSON GROUP PLC 7.8% 4,323,059 -2.4% 0.39% $859,415,657
Artisan Partners Limited Partnership 6.7% 3,720,880 -6.8% 1.1% $739,748,153
Capital International Investors 5.5% 3,060,616 +0.45% 0.1% $608,481,067
T. Rowe Price Investment Management, Inc. 4.8% 2,666,618 -26% 0.32% $530,151,000
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 3.4% 1,882,781 -1% 0.12% $374,315,689
WELLINGTON MANAGEMENT GROUP LLP 3.2% 1,798,931 +96% 0.06% $357,645,472
PRICE T ROWE ASSOCIATES INC /MD/ 3.1% 1,726,228 -8% 0.04% $343,192,000
FRANKLIN RESOURCES INC 2.9% 1,589,956 -9.3% 0.08% $316,099,066
PERCEPTIVE ADVISORS LLC 2% 1,088,501 +13% 6.3% $216,404,884
Invesco Ltd. 1.7% 917,903 -3.1% 0.03% $182,488,296
Polar Capital Holdings Plc 1.5% 857,911 +2.4% 0.82% $170,561,286
PRINCIPAL FINANCIAL GROUP INC 1.4% 793,677 +2723% 0.08% $157,790,924
GOLDMAN SACHS GROUP INC 1.2% 653,012 +21% 0.02% $129,825,315
Vestal Point Capital, LP 1.1% 600,000 +200% 5.4% $119,286,000
AMERIPRISE FINANCIAL INC 1% 562,936 -4.3% 0.03% $111,917,306
AMERICAN CENTURY COMPANIES INC 0.98% 544,606 +2.6% 0.06% $108,274,297
FIL Ltd 0.83% 459,340 -1% 0.07% $91,321,385
BlackRock, Inc. 0.81% 451,497 -4.3% 0% $89,762,118
MORGAN STANLEY 0.73% 406,761 +60% 0% $80,868,155
Spyglass Capital Management LLC 0.7% 388,647 4.1% $77,266,910
ALLIANCEBERNSTEIN L.P. 0.68% 375,899 -0.48% 0.02% $74,732,480

Institutional Holders of Ascendis Pharma A/S - ADR (ASND) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 69,572 $14,835,473 +$1,284,512 21,324% 7
2025 Q3 63,798,122 $12,683,766,165 +$232,138,542 19,881% 276
2025 Q2 62,895,390 $10,855,906,781 -$373,772,963 17,260% 245
2025 Q1 65,178,531 $10,147,207,193 +$223,137,113 15,586% 240
2024 Q4 63,749,884 $8,776,087,969 +$115,852,691 13,767% 211
2024 Q3 62,595,715 $9,312,956,236 +$237,477,944 14,931% 219
2024 Q2 60,582,608 $8,262,207,594 -$25,108,613 13,638% 201
2024 Q1 60,784,496 $9,188,391,576 +$194,926,420 15,117% 189
2023 Q4 112,956 $14,252,894 +$9,813,773 12,595% 4
2023 Q3 60,251,885 $5,641,966,523 -$73,659,278 9,364% 155
2023 Q2 61,001,517 $5,444,384,091 -$43,596,050 8,925% 153
2023 Q1 60,956,874 $6,532,348,001 -$599,238,692 10,722% 158
2022 Q4 65,905,596 $8,048,128,736 -$71,111,968 12,213% 179
2022 Q3 66,592,808 $6,878,323,319 +$156,051,485 10,326% 172
2022 Q2 63,199,728 $5,874,503,143 +$101,790,666 9,295.99% 160
2022 Q1 61,917,032 $7,265,683,213 +$414,385,574 11,736% 167
2021 Q4 58,360,734 $7,849,241,391 -$60,375,593 13,453% 166
2021 Q3 57,994,758 $9,242,685,600 +$506,032,986 15,939% 163
2021 Q2 55,035,436 $7,237,845,901 +$271,910,179 13,154.99% 170
2021 Q1 52,654,712 $6,793,004,689 -$266,902,917 12,887.97% 171
2020 Q4 54,090,162 $9,020,976,490 +$126,944,869 16,678.02% 169
2020 Q3 53,309,147 $8,226,712,101 +$764,432,402 15,431.99% 148
2020 Q2 48,248,343 $7,132,005,530 +$38,828,525 14,789.98% 149
2020 Q1 47,865,751 $5,390,563,456 +$190,930,122 11,260.95% 142
2019 Q4 46,138,165 $6,418,677,137 -$13,135,201 13,911.99% 138
2019 Q3 46,121,663 $4,442,424,426 -$194,323,622 9,632% 126
2019 Q2 47,663,417 $5,487,484,115 +$237,889,859 11,515.01% 132
2019 Q1 45,989,019 $5,412,737,939 +$712,057,309 11,770% 137
2018 Q4 40,100,469 $2,509,199,237 -$10,826,185 6,264.99% 102
2018 Q3 40,188,306 $2,847,498,166 +$44,455,447 7,086% 94
2018 Q2 39,572,741 $2,632,378,192 +$96,236,760 6,652% 99
2018 Q1 38,126,373 $2,493,396,132 +$345,130,806 6,539.99% 89
2017 Q4 30,513,340 $1,222,363,447 +$52,891,520 4,005.97% 64
2017 Q3 28,774,674 $1,040,063,755 +$201,305,468 3,624.99% 59
2017 Q2 23,269,447 $646,000,000 +$76,066,932 2,776% 34
2017 Q1 20,898,775 $585,169,000 +$9,050,404 2,800.03% 34
2016 Q4 20,561,164 $416,158,000 +$130,782,705 2,024% 30
2016 Q3 13,995,656 $281,311,000 +$4,791,136 2,009.99% 22
2016 Q2 13,876,594 $184,147,000 +$10,182,250 1,326.99% 23
2016 Q1 12,036,579 $223,242,000 +$9,842,698 1,855.03% 25
2015 Q4 10,090,990 $184,865,000 +$3,824,983 1,831.97% 24
2015 Q3 7,464,711 $132,122,000 +$7,983,334 1,769.93% 23
2015 Q2 8,953,588 $157,819,000 -$7,995,077 1,767.68% 31
2015 Q1 7,454,340 $128,058,000 +$128,058,095 1,734.96% 34